Gefarnate

Gefarnate
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A02BX07 (WHO) ;
Identifiers
	IUPAC name (2E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate;
CAS Number	51-77-4 ;
PubChem CID	5282182;
ChemSpider	4445377 ;
UNII	1ISE2Y6ULA;
KEGG	D01529 ;
ChEMBL	ChEMBL2105085 ;
Chemical and physical data
Formula	C27H44O2
Molar mass	400.647 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(C)/CCC=C(C)C;
	InChI InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+ ; Key:ZPACYDRSPFRDHO-ROBAGEODSA-N ;
	(what is this?) (verify)

Gefarnate is a drug used for the treatment of gastric ulcers.^[1]

It also has been proposed for use in the treatment of dry eye syndrome.^[2]^[3]

References

^ Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone". Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487.
^ Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. PMID 18560615.
^ Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf. 2 (2): 131–48. doi:10.1016/s1542-0124(12)70149-0. PMID 17216084.^{[permanent dead link]}

This article about an alkene is a stub. You can help Wikipedia by expanding it.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

v t e Drugs for peptic ulcer and GERD/GORD (A02B)
H₂ antagonists ("-tidine")	Cimetidine Famotidine Lafutidine Lavoltidine (loxtidine) Nizatidine Ranitidine^#‡ Roxatidine
Prostaglandins (E)/ analogues ("-prost-")	Misoprostol Enprostil
Proton-pump inhibitors ("-prazole")	Azeloprazole Dexlansoprazole Esomeprazole Ilaprazole Lansoprazole Omeprazole^# Pantoprazole Picoprazole Rabeprazole Tenatoprazole Timoprazole
Potassium-competitive acid blockers ("-prazan")	Linaprazan Revaprazan Soraprazan Vonoprazan
Others	Aceglutamide aluminum Acetoxolone Alginic acid Arbaclofen placarbil Bismuth subcitrate Carbenoxolone Cetraxate Gefarnate Irsogladine Lesogaberan Pirenzepine Proglumide Rebamipide Sucralfate Sulglicotide Telenzepine Teprenone Troxipide Zinc L-carnosine Zolimidine
Combinations	Bismuth subcitrate/metronidazole/tetracycline Omeprazole/amoxicillin/rifabutin Vonoprazan/amoxicillin Vonoprazan/amoxicillin/clarithromycin
See also: Helicobacter pylori* eradication protocols*
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III